Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").
D000328:Adult; D000661:Amphetamine / Q000627:therapeutic use; D000818:Animals; D003863:Depression / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D010259:Paranoid Disorders / Q000188:drug therapy; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy
D008996:Monoamine Oxidase Inhibitors; D000661:Amphetamine